20715 Background: Myelosuppression is one of the most relevant side effects of cancer chemotherapy (CT). To date its impact on blood component (BC) use and cost is not well characterised. Methods: Prospective, observational study to determine BC use and associated costs in NSCLC and lymphoma patients (pts). Pts were enrolled consecutively at the start of 1st or 2nd line (immuno-)CT at an academic cancer center in Germany (01/05–06/06). Pts receiving myeloablative CT with peripheral blood stem cell support were excluded. Clinical data and consumption of BC were collected from medical charts. Costs of BC are presented from provider perspective. Results: 180 pts undergoing 633 CT cycles were evaluable (Mean age 59 yrs, 47% NSCLC, 53% lymphoma, 68% stage III/IV, 86% ECOG ≤1). During 11% of CT cycles BC were transfused to 27% of pts (n=49; lymphoma n=22; NSCLC n=27). Fourty six pts (26%) were substituted with red blood cells (RBC), 8 (4%) and 3 (2%) with platelets (PLT) and fresh frozen plasma (FFP). In total, 310 units of blood were consumed (210 RBC, 49 PLT and 51 FFP). Mean number of transfused units (TU) per patient with transfusion amounted to 6.3±5.2 and varied between 4.3±4.9 for NSCLC and 8.9±16.0 for lymphoma pts. The table shows mean BC costs per patient with transfusion stratified by tumour type. Conclusions: Haematotoxicity has significant impact on BC use and associated costs in NSCLC and lymphoma pts. In lymphoma pts BC costs are higher than in pts with NSCLC. Number of TU is highest for RBC. BC costs are highest for pts with PLT transfusion. All (n=49) Lymphoma (n=22) NSCLC (n=27) Total 626.0 (1,484.0) 1,009.7 (2,136.6) 314.0 (391.4) RBC 309.7 (266.9) 389.5 (353.7) 248.4 (155.5) PLT 1,831.5 (2,465.6) 2,193.7 (2,793.1) 745.0 (632.2) FFP 596.3 (462.3) 630.5 (648.4) 548.0 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen Amgen, Eli Lilly
原文链接
分享
引用
